Kuihua Shuangshen drop pill, a traditional Chinese medicine developed by Kuihua Pharmaceuticals to treat hepatitis B, has recently passed phase II clinical trials. The new drug has been tested in 146 patients in six hospitals, including PLA No. 302 Hospital, Beijing Ditan Hospital, and Youan Hospital. The data derived from the clinical trials shows a therapeutic effect equivalent to the interferon, a western medicine currently applied to treat hepatitis B, demonstrating the success of phase II clinical trials. The new drug is able to turn e antigens in patients' body into negative, and treat the patients through regulating patients' immune system. As a major breakthrough in developing new hepatitis B drugs, the drop pill enjoys numerous merits, including easy medication, small side effects, economic, safe and reliable, with fine application perspective. The new drug will be put into bulk production when its therapeutic effects are further confirmed in phase III clinical trials.